Gilead Sciences, Inc. (GILD) — Analyst outlook / Analyst consensus target is. Based on 58 analyst ratings, the consensus is bullish — 37 Buy, 20 Hold, 1 Sell.
The consensus price target is $158.71 (low: $105.00, high: $180.00), representing an upside of 13% from the current price $140.45.
Analysts estimate Earnings Per Share (EPS) of $4.41 and revenue of $28.32B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.38 vs est $4.41 (missed -91.4%). 2025: actual $6.84 vs est $8.11 (missed -15.7%). Analyst accuracy: 0%.
GILD Stock — 12-Month Price Forecast
$158.71
▲ +13.00% Upside
Average Price Target
Based on 58 Wall Street analysts offering 12-month price targets for Gilead Sciences, Inc., the average price target is $158.71, with a high forecast of $180.00, and a low forecast of $105.00.
The average price target represents a +13.00% change from the last price of $140.45.
Highest Price Target
$180.00
Average Price Target
$158.71
Lowest Price Target
$105.00
GILD Analyst Ratings
Buy
Based on 58 analysts giving stock ratings to Gilead Sciences, Inc. in the past 3 months
EPS Estimates — GILD
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.38
vs Est $4.41
▼ 1,060.5% off
2025
Actual $6.84
vs Est $8.11
▼ 18.6% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is improving.
Revenue Estimates — GILD
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $28.754B
vs Est $28.320B
▲ 1.5% off
2025
Actual $29.443B
vs Est $29.229B
▲ 0.7% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
